 The objective of the study is to assess the safety and efficacy of the IMPELLA 2.5 System in subjects undergoing non-emergent high-risk percutaneous coronary intervention PCI post market approval. The primary endpoint will be a composite clinical endpoint of major adverse events through 90 days following the PCI procedure. The outcome will be compared to the pre specified performance goal of 53. 